Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Carcinoma of unknown primary site.

Varadhachary GR, Raber MN.

N Engl J Med. 2014 Nov 20;371(21):2040. doi: 10.1056/NEJMc1411384. No abstract available.

PMID:
25409386
2.

Cancer of unknown primary site.

Varadhachary GR, Raber MN.

N Engl J Med. 2014 Aug 21;371(8):757-65. doi: 10.1056/NEJMra1303917. Review. No abstract available.

PMID:
25140961
3.

Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.

Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, Greco FA.

Int J Clin Oncol. 2014;19(3):479-84. doi: 10.1007/s10147-013-0583-0. Epub 2013 Jun 28.

PMID:
23813044
4.

A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.

Carlson H, Lenzi R, Raber MN, Varadhachary GR.

Int J Clin Oncol. 2013 Apr;18(2):226-31. doi: 10.1007/s10147-011-0366-4. Epub 2012 Jan 5.

PMID:
22218909
5.

Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary.

Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN.

Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599. Epub 2011 Apr 29.

6.

Coagulation Tests.

Raber MN.

In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 157.

7.

Emerging techniques for determining the tissue of origin in patients with unknown primary carcinoma.

Raber MN.

Expert Opin Med Diagn. 2010 Nov;4(6):455-7. doi: 10.1517/17530059.2010.516746. Epub 2010 Sep 25.

PMID:
23496226
8.

Carcinoma of unknown primary origin: on the cusp of a new era.

Raber MN.

Cancer J. 2010 Jan-Feb;16(1):66-7. doi: 10.1097/PPO.0b013e3181ce4769. No abstract available.

PMID:
20164693
9.

Gene expression profiling in cancers of unknown primary.

Varadhachary GR, Raber MN.

J Clin Oncol. 2009 Sep 1;27(25):e85-6; author reply e87-8. doi: 10.1200/JCO.2009.23.7644. Epub 2009 Jul 27. No abstract available.

PMID:
19635993
10.

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD.

J Clin Oncol. 2008 Sep 20;26(27):4442-8. doi: 10.1200/JCO.2007.14.4378.

PMID:
18802157
11.

Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.

Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL.

Lancet Oncol. 2008 Jun;9(6):596-9. doi: 10.1016/S1470-2045(08)70151-7.

PMID:
18510991
12.

Metastatic patterns in adenocarcinoma.

Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL.

Cancer. 2006 Apr 1;106(7):1624-33.

13.

A patient's perspective on cancer-related fatigue.

Raber MN.

Cancer. 2001 Sep 15;92(6 Suppl):1662-3. No abstract available.

PMID:
11598883
14.

Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma.

Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL.

Clin Cancer Res. 1999 Nov;5(11):3403-10.

15.

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.

Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL.

Ann Oncol. 1998 Sep;9(9):1003-8.

16.

Unknown primary tumors metastatic to liver.

Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL.

J Clin Oncol. 1998 Jun;16(6):2105-12.

PMID:
9626210
17.
18.

Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?

Lenzi R, Hess KR, Abbruzzese MC, Raber MN, OrdoƱez NG, Abbruzzese JL.

J Clin Oncol. 1997 May;15(5):2056-66.

PMID:
9164218
19.

Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.

Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN.

Clin Cancer Res. 1996 Sep;2(9):1489-97.

20.

Are time or intensity factors important to the definition of metastases of unknown origin?

Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR.

J Natl Cancer Inst. 1996 Apr 3;88(7):462-3. No abstract available.

PMID:
8618241
21.

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.

Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK.

J Clin Oncol. 1996 Feb;14(2):503-13.

PMID:
8636764
22.

Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.

Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN.

J Clin Oncol. 1996 Jan;14(1):287-95.

PMID:
8558210
23.

Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer.

Hoffman K, Holmes FA, Fraschini G, Esparza L, Frye D, Raber MN, Newman RA, Hortobagyi GN.

Cancer Chemother Pharmacol. 1996;37(3):254-8.

PMID:
8529286
24.

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin.

Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN.

J Clin Oncol. 1995 Aug;13(8):2094-103.

PMID:
7636553
25.

Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors.

Lee JS, Newman RA, Lippman SM, Fossella FV, Calayag M, Raber MN, Krakoff IH, Hong WK.

J Clin Oncol. 1995 Jun;13(6):1501-8.

PMID:
7751898
26.

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients.

Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P.

J Clin Oncol. 1994 Jun;12(6):1272-80.

PMID:
8201389
27.

Phase II clinical trial of didemnin B in previously treated small cell lung cancer.

Shin DM, Holoye PY, Forman A, Winn R, Perez-Soler R, Dakhil S, Rosenthal J, Raber MN, Hong WK.

Invest New Drugs. 1994;12(3):243-9. Review.

PMID:
7896544
28.

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN.

Cancer Treat Rev. 1993 Oct;19(4):351-86. Review.

PMID:
8106152
29.

The biology of unknown primary tumors.

Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P.

Semin Oncol. 1993 Jun;20(3):238-43. Review. No abstract available.

PMID:
8503019
30.

Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.

Lee JS, Newman RA, Lippman SM, Huber MH, Minor T, Raber MN, Krakoff IH, Hong WK.

J Clin Oncol. 1993 May;11(5):959-66.

PMID:
8487058
31.

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et al.

J Natl Cancer Inst. 1993 Mar 3;85(5):384-8.

PMID:
8094466
32.
33.
34.

Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin.

Lenzi R, Raber MN, Frost P, Schmidt S, Abbruzzese JL.

Eur J Cancer. 1993;29A(11):1634. No abstract available.

PMID:
8217373
35.

Clinical pharmacology of combined oral uracil and ftorafur.

Ho DH, Covington WP, Pazdur R, Brown NS, Kuritani J, Newman RA, Raber MN, Krakoff IH.

Drug Metab Dispos. 1992 Nov-Dec;20(6):936-40.

PMID:
1362949
36.

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.

Fossella FV, Winn RJ, Holoye PY, Hallinan B, Raber MN, Hoelzer K, Young JA, Readling J, Bowers B, Hong WK.

Invest New Drugs. 1992 Nov;10(4):331-5.

PMID:
1336771
37.

Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer.

Benvenuto JA, Newman RA, Bignami GS, Raybould TJ, Raber MN, Esparza L, Walters RS.

Invest New Drugs. 1992 Jul;10(2):113-7.

PMID:
1500265
38.

Phase I trial and clinical pharmacology of elsamitrucin.

Raber MN, Newman RA, Newman BM, Gaver RC, Schacter LP.

Cancer Res. 1992 Mar 15;52(6):1406-10.

39.

Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteine.

Benvenuto JA, Ayele W, Legha SS, Raber MN, Nicaise C, Newman RA.

Anticancer Drugs. 1992 Feb;3(1):19-23.

PMID:
1623211
40.

Unknown primary tumors.

Raber MN, Abbruzzese JL, Frost P.

Curr Opin Oncol. 1992 Feb;4(1):3-9. No abstract available.

PMID:
1591292
41.

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN.

J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805.

PMID:
1683908
42.

Phase I trial of FK973: description of a delayed vascular leak syndrome.

Pazdur R, Ho DH, Daugherty K, Bradner WT, Krakoff IH, Raber MN.

Invest New Drugs. 1991 Nov;9(4):377-82.

PMID:
1804817
43.

Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma.

Fossella FV, Winn RJ, Holoye PY, Raber MN, Holden L, Belt R, Allen H, Hallinan B, Harper K.

Invest New Drugs. 1991 Nov;9(4):375-6. No abstract available.

PMID:
1666631
44.
45.

Phase I studies of trimetrexate using single and weekly dose schedules.

Huan SD, Legha SS, Raber MN, Krakoff IH.

Invest New Drugs. 1991 May;9(2):199-206.

PMID:
1831442
46.

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al.

J Clin Oncol. 1991 Mar;9(3):491-8.

PMID:
1999720
47.

Phase II clinical trial of 4'-O-tetrahydropyranyl-adriamycin (THP-adriamycin) in recurrent squamous cell carcinoma of the head and neck.

Shin DM, Kramer AM, Dimery IW, Raber MN, Ewer M, Hong WK.

Invest New Drugs. 1991 Feb;9(1):89-91.

PMID:
2026488
48.

Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.

Dhingra HM, Murphy WK, Winn RJ, Raber MN, Hong WK.

Invest New Drugs. 1991 Feb;9(1):69-72. No abstract available.

PMID:
1709153
49.

Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies.

Sandles LG, Freedman RS, Raber MN, Kavanagh J, Edwards CL, Scott WR, Wharton JT.

Gynecol Oncol. 1990 Nov;39(2):139-45.

PMID:
2121628
50.

Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).

Perez-Soler R, Lopez-Berestein G, Lautersztain J, al-Baker S, Francis K, Macias-Kiger D, Raber MN, Khokhar AR.

Cancer Res. 1990 Jul 15;50(14):4254-9.

Supplemental Content

Loading ...
Support Center